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Background:We and others have identified the aldo-keto reductase AKR1C3 as a potential drug target in prostate cancer, breast
cancer and leukaemia. As a consequence, significant effort is being invested in the development of AKR1C3-selective inhibitors.
Methods: We report the screening of an in-house drug library to identify known drugs that selectively inhibit AKR1C3 over the
closely related isoforms AKR1C1, 1C2 and 1C4. This screen initially identified tetracycline as a potential AKR1C3-selective inhibitor.
However, mass spectrometry and nuclear magnetic resonance studies identified that the active agent was a novel breakdown
product (4-methyl(de-dimethylamine)-tetracycline (4-MDDT)).
Results: We demonstrate that, although 4-MDDT enters AML cells and inhibits their AKR1C3 activity, it does not recapitulate the
anti-leukaemic actions of the pan-AKR1C inhibitor medroxyprogesterone acetate (MPA). Screens of the NCI diversity set and an
independently curated small-molecule library identified several additional AKR1C3-selective inhibitors, none of which had
the expected anti-leukaemic activity. However, a pan AKR1C, also identified in the NCI diversity set faithfully recapitulated the
actions of MPA.
Conclusions: In summary, we have identified a novel tetracycline-derived product that provides an excellent lead structure with
proven drug-like qualities for the development of AKR1C3 inhibitors. However, our findings suggest that, at least in leukaemia,
selective inhibition of AKR1C3 is insufficient to elicit an anticancer effect and that multiple AKR1C inhibition may be required.
Members of the aldo/keto reductase (AKR) superfamily catalyse
the conversion of aldehydes and ketones to their corresponding
alcohols by utilising NADH and/or NADPH as cofactors. We and
others have identified AKR1C3 as a potentially novel therapeutic
target in prostate cancer, breast cancer and leukaemia (Desmond
et al, 2003; Byrns and Penning, 2009; Houghton et al, 2011; Byrns
et al, 2012; Mitsiades et al, 2012). Our studies in acute myeloid
leukaemia (AML) have demonstrated that enforced AKR1C3
overexpression represses the all-trans retinoic acid (ATRA)-
induced differentiation of HL-60 AML cells (Desmond et al, 2003),
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whereas conversely knockdown of AKR1C3 in K562 cells results in
erythroid differentiation (Birtwistle et al, 2009). We have also
shown that the known AKR inhibitors, indomethacin and
medroxyprogesterone acetate (MPA), promote the differentiation
and apoptosis of AML cells (Bunce et al, 1994; Khanim et al,
2009a). More recently, we have demonstrated that MPA in
combination with bezafibrate (BEZ) has in vivo clinical activity
against AML (Murray et al, 2010). We have therefore proposed
AKR1C3 as a novel regulator of myeloid cell differentiation and a
potential new therapeutic target in leukaemia.
The role of AKR1C3 in prostate and breast cancer has been
predominantly inferred by virtue of altered mRNA and/or protein
expression levels in tumour tissues and in association with disease
progression (Agung et al, 2005; Suzuki et al, 2005; Hofland et al,
2010; Beckmann et al, 2011; Aderibigbe et al, 2012; Jamieson et al,
2012), and the enzyme’s recognised 3,alpha- and 17,beta-
hydroxysteroid activities and 9,alpha-11,beta prostaglandin D2
(9a, 11b-PGD2) dehydrogenase activity (Matsuura et al, 1998;
Kuhne et al, 2001; Byrns and Penning, 2009; Byrns et al, 2012).
Byrns et al (2012) demonstrated that overexpression of AKR1C3 in
LNCaP prostate cancer cells resulted in increased testosterone
production and resistance to finasteride. Single-nucleotide
polymorphisms in AKR1C3 have been associated with disease
progression and aggressiveness in prostate carcinomas (Izumoto
et al, 2005; Richards et al, 2006). AKR1C3 polymorphisms have
also been shown to modulate the risk of other cancers, including
bladder cancer, childhood leukaemias and diffuse large B-cell
lymphoma (Bauman et al, 2004; Morakinyo et al, 2011; Adegoke
et al, 2012c). Separately, it has been shown that AKR1C3 can
inactivate and induce resistance to the anticancer drugs doxo-
rubicin, oracin and cisplatin (Adegoke and Nyokong, 2012;
Adegoke et al, 2012a, b), whereas elevated AKR1C3 protein
levels were associated with radioresistance in non-small cell lung
carcinomas (Jamieson et al, 2012).
AKR1C3 belongs to a highly conserved AKR subfamily
(in humans AKR1C1, -1C2, -1C3 and -1C4), which displays
differential tissue expression and possess overlapping but differing
pleiotropic activities (Kuhne et al, 2001; Gratacos-Cubarsi et al,
2007; Birtwistle et al, 2009; Velica et al, 2009; Rizner and Penning,
2013). MPA does not display strong AKR1C3 selectivity amongst
this family and only inhibits AKR1C3 at doses higher than those
used for its respective primary indications as a contraceptive
steroid. These considerations have driven many research groups to
search for lead compounds with a greater selectivity towards
AKR1C3 that could be developed as novel cancer therapies
(Halling-Sorensen et al, 2002; Ghia et al, 2003; Qiu et al, 2007;
Zargar et al, 2011; Burnett et al, 2012; Giebel et al, 2013; Hebert
et al, 2013; Wasylishen et al, 2013). In recognition of this, several
laboratories have undertaken structural studies of AKR1C3 bound
to inhibitors and substrates and embarked on the identification of
lead compounds for drug development (Zargar et al, 2011; Burnett
et al, 2012; Hebert et al, 2013; Wasylishen et al, 2013).
New drug development is challenging and as the pharmacologist
and Nobel laureate James Black is quoted as saying, ‘the most
fruitful basis for the discovery of a new drug is to start with an old
drug’. In order to screen existing drugs for greater selective
AKR1C3 inhibition, we developed a high-throughput assay of
AKR1C1, -1C2, -1C3 and -1C4 activity based on the consumption
of NADPH in the presence of the pan-AKR1C substrate
phenanthrenequinone (PQ) (AKR1C-diaphorase assay). An initial
screen of an in-house custom-built library of 100 off-patent drugs
(FMC1) identified tetracycline as a potential AKR1C3-selective
inhibitor. However, mass spectrometry and nuclear magnetic
resonance (NMR) studies identified that the active agent was in
fact a novel tetracycline breakdown product (4-methyl(de-
dimethylamine)-tetracycline (4-MDDT). We demonstrate here
that this novel agent enters AML cells and inhibits the AKR1C3
activity within, but unexpectedly does not recapitulate the anti-
leukaemic actions of the pan-AKR1C3 inhibitor MPA either alone
or in combination with BEZ. Further screens of the NCI diversity
set (http://dtp.cancer.gov) and of a small-molecule library curated
at the Cancer Research Technology (CRT) identified several
additional AKR1C3-selective inhibitors. Importantly, none of these
AKR1C3-selective compounds had anti-leukaemic activity. How-
ever, a pan AKR1C1, -1C2, -1C3 inhibitor also identified in the
NCI diversity set faithfully recapitulated the actions of MPA.
MATERIALS AND METHODS
FMC100 drug library. All drugs were purchased from Sigma-
Aldrich (Poole, UK). Stocks were prepared at 10 000 reported
peak serum concentrations in dimethylsulphoxide DMSO, ethanol
or water and stored at  20 1C. Tetracycline hydrate (Sigma-
Aldrich) was prepared at 225mM in DMSO.
National cancer institute diversity set. NCI compounds were
ordered from the NCI/DTP Open Chemical Repository (http://
www.dtp.nci.nih.gov). Stocks were prepared as 10mM in DMSO in
96-well plates and stored at  20 1C.
Cancer research technologies (CRT). A1, A6 and A9 were
identified as AKR1C3-selective inhibitors by CRT using a
fluorescence-based assay and purified recombinant AKR1C1-4
proteins (Hebert et al, 2013). Compounds A1((CRT0036521)
3-(3,4-dihydro-1H-isoquinoline-2-sulphonyl)-benzoic acid), A6
((CRT0083914) 1-[4-(2-methyl-piperidine-1-sulphonyl)-phenyl]-
pyrrolidin-2-one), and A9 ((CRT0093964) [4-(4-chloro-phenyl)-
piperazin-1-yl]-morpholin-4-yl-methanone)(Figure 7A), were pro-
vided as 12–15mM stocks in anhydrous DMSO and stored at 4 1C.
Production and purification of recombinant AKR1C proteins.
N-terminally Hisx6-tagged recombinant AKR1C1, 2, 3 and 4 were
cloned into pET28b vectors (Novagen, Darmstadt, Germany) and
expressed and purified as previously described (Lovering et al,
2004; Davies et al, 2009).
High-throughput recombinant AKR1C-diaphorase assay.
Supplementary Figure 1 shows a schematic for the fluorometric
AKR1C activity assay using PQ. Compounds were screened against
purified recombinant AKR1C1, 2, 3 and 4 proteins in duplicate
wells of 96-well plates. In the first step, reactions contained 4mM
PQ, 5 mM b-NADPH, 15 mg recombinant AKR1C (recAKR1C)
protein and 100 mM test compound in 50mM potassium phosphate
buffer (pH 6.5). Dimethylsulphoxide and acetonitrile were both
present at 2% (v/v) each. Negative, positive and no-inhibitor
control wells were set in duplicate on each plate; negative control
had no PQ, while the positive controls used 5mM MPA or 20mM
indomethacin. The assay as used measured uncompetitive inhibi-
tion owing to the formation of the E–NADPþ –I complex (Byrns
et al, 2012). PQ was non-limiting in this assay as the product
spontaneously oxidises back to PQ, as determined by the
restoration of the initial rate of NADPH consumption when
NADPH was re-added to the assay (Supplementary Figure 1B).
Plates were incubated at 37 1C for 15min before resazurin
and diaphorase were added to final concentrations of 26.8mM
and 0.54U/ml, respectively. The contents of wells were mixed
by repeated pipetting and plates incubated for a further 10min at
37 1C. Fluorescence was measured (Ex530 nm/Em595 nm) in a
fluorimeter (Bio-Tek Instruments, Winooski, VT, USA) using the
KC4 software (BioTek, Potten, UK). Dose titration experiments to
calculate IC50 values were performed as above. Percentage enzyme
activity was calculated using 100 (100 (RB1)/(B0B1)),
where R is A530/590 of well with test compound, B1 is average of
A530/590 of duplicate wells without compound and B0 is average
A530/590 reading of duplicate wells without substrate.
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NADPH assay for AKR1C enzymatic activity. Assays for all four
human recombinant AKR1C enzymes were performed, as
described previously (Davies et al, 2009).
HPLC purification of tetracycline breakdown product
4-MDDT. 4-MDDT was purified at room temperature using
a Dionex DX-600 HPLC system (Thermo Scientific, Hemel
Hempstead, UK), Prevail Select C18 5 m (250mm 4.6mm i.d.)
HPLC column. Elution at a flow of 1ml/min was performed with a
linear gradient between solvent A (50% methanol : 0.1% trifluor-
oacetic acid v/v) and solvent B (98% methanol : 0.1% trifluoroacetic
acid v/v). Peak identification was performed by comparing spectra
(collected between 220 and 500 nm). Fractions were collected,
dried down under nitrogen stream and 4-MDDT resuspended in
DMSO at 50mM using its molecular mass as 413, as measured by
GC-MS analysis (see below).
Mass spectrometry and NMR. Mass spectrometry to define mass
was performed by Dr Peter Ashton (School of Chemistry,
University of Birmingham) on both freshly prepared tetracycline
and HPLC-purified tetracycline derivative (4-MDDT) by electro-
spray mass spectrometry analysis, scanning for molecules with
RMM 200–2000.
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Figure 1. Identification of a novel tetracycline breakdown product. (A) A panel of 100 clinically licensed drugs (FMC100) at peak serum
concentrations was screened for AKR1C-inhibitory activity against recombinant purified AKR1C proteins using the AKR1C-diaphorase assay.
Data shown is mean fluorescence arbitrary units. Black bars indicate tetracycline and the dashed line represents level of inhibition by 5 mM MPA.
GC-MS and NMR were used to elucidate the structure of the novel tetracycline breakdown product 4-methyl,(didemethyl)-tetracycline (4-MDDT).
(B) Structures and names of the parent tetracycline and novel tetracycline breakdown product. (C) The isoform specificity of HPLC-purified 4-MDDT
was determined against recombinant AKR1C proteins using the AKR1C-daphorase assay (see Materials and Methods). (D) The IC50 of 4-MDDT for
recombinant AKR1C3 protein was determined using the PQ assay (see Materials and Methods).
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To elucidate the structure, 1D and 2D NMR experiments were
performed on both 10mM freshly prepared tetracycline and HPLC-
purified tetracycline derivative (4-MDDT). Spectra were recorded
on a Bruker 500MHz spectrometer (Bruker, Coventry, UK) and a
Bruker 600MHz spectrometer (Bruker), both equipped with
cryogenically cooled probes. All spectra were recorded at a
temperature of 300K, in either d6-DMSO or d3-acetonitrile.
One-dimensional 1H NMR spectra were acquired using a spectral
width of 7.2 kHz and 32K data points. One-dimensional 13C NMR
spectra were obtained using a spectral width of 24 kHz with 64K
data points. One-dimensional 15N NMR spectra were obtained
using a spectral width of 25 kHz with 32K data points. For further
assignments verification, 2D COSY, TOCSY (100ms mixing time)
and NOESY (200ms mixing time) spectra were obtained, along with
13C-HSQC and 15N-HSQC (with the INEPT delay adjusted for
short and for long-range couplings) in order to identify NH and
N(CH3)2 groups.
In silico docking studies. Simulated docking of tetracycline and
4-MDDT into AKR1C3 (PDB ID 1S2C with flufenamic acid
removed) was performed using Autodock 4.2 (Wu et al, 2010). The
coordinates of tetracycline with Mg2þ were adapted from the
crystal structure PDB ID 2TCT. The coordinates of 4-MDDT were
calculated by editing the tetracycline coordinates using PyMol.
UCSF Chimera 1.6.2 (Li et al, 2010) was used to calculate AM-1
BCC charges for ligands in different proton configurations with/
without Mg2þ . Polar hydrogen atoms and partial charges for the
protein and NADPH cofactor were calculated using the standard
settings in MGLTools. The input and output files for Autodock
were processed using the standard MGLTools scripts. The centre of
the docking site was the average coordinate of the flufenamic acid
bound in PDB 1S2C.
A number of calculations included some flexibility of the
AKR1C3 structure by allowing torsional rotation of residues
having the most contact with the ligand (ASN167, PHE306,
PHE311, TYR216, TRP227, LEU54, LEU128, SER129, LEU122,
TRP86, MET120). In addition, the two magnesium-bound 4-
MDDT configurations were docked with the same flexible residues
as above but removing TYR216 and MET120 from the list and
adding ARG226.
Cell culture and drug treatments. HL60, KG1a and K562
(ATCC) cell lines were maintained in RPMI-1640 medium with
L-glutamine supplemented with 10% v/v heat-inactivated
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Figure 2. In silico docking of 4-MDDT into the crystal structure of AKR1C3. (A) Autodock was used to dock 4-MDDT into our previously published
AKR1C3 crystal structure after flufenamic acid was removed (PDB ID 1S2C)[39]. The 4-MDDT is coloured by atom type (green: carbon, red: oxygen,
white: hydrogen) and shown as sticks, with magnesium a green sphere. The NADPþ cofactor is coloured yellow and the protein is rendered as an
aquamarine cartoon ribbon. Side chains identified as potentially providing specificity are shown as sticks and labelled. (B) Close-up of the
predicted binding sites and key interacting amino-acid residues. (C) Protein Sequence alignment of AKR1C1-4 with the key interacting amino-acid
residues highlighted in boxes.
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fetal bovine serum and penicillin (100 units/ml)/streptomycin
(100 mg/ml) (all from Gibco, Invitrogen Ltd, Paisley, UK) at 37 1C
with 5% CO2. Cells were passaged every 2 days maintaining cell
densities between 0.25–1.5 106 cells/ml. Drug treatments in 96-
well plate assays were performed using 1 104 cells/well in 200 ml,
or in flasks at 0.25 106 cells/ml in 4ml media. Appropriate
volumes of DMSO and/or ethanol were added as solvent controls
in control treatments.
Chronic lymphocytic leukaemia (CLL) cells. Chronic lymphocytic
leukaemia blood samples were obtained from unselected patients
diagnosed with CLL, according to standard morphologic,
immunophenotypic and clinical criteria, attending the outpatient
clinic at Birmingham Heartlands Hospital following informed
written consent for the study, which had received local ethical
approval. Primary mononuclear cells were prepared using Ficoll
Paque-Plus (Anachem, Luton, UK) as previously described.
Resultant cells were cultured and treated in a 96-well plate
co-culture system, with L-control fibroblasts, as described
previously (Hayden et al, 2010). Viability was assessed at 24 h
using annexin V and propidium iodide staining, and flow
cytometry (Hayden et al, 2010).
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Figure 3. 4-MDDT does not recapitulate the actions of MPA against AML cell lines. HL-60, K562 and KG1a cells were treated for 7 days with
either solvent control, 50mM 4-MDDT or 5 mM MPA, alone or in combination with 0.5mM BEZ. (A) Cumulative cell counts for HL60, K562 and KG1a
after 7 days treatment. Data shown is mean of a minimum of N¼3 experiments±s.e.m. (B and D) HL60 differentiation was assessed at day 7 by
staining for CD11b and flow cytometry following treatment with either solvent control, 50mM 4-MDDT or 5mM MPA with or without 0.5mM BEZ or
10 nM ATRA. Data shown is mean of a minimum of N¼ 3 experiments±s.e.m. (C) Cytospins of HL60 cells treated for 7 days as described above
were stained with Jenner–Giemsa to demonstrate changes in cell morphology. (E) Intracellular AKR1C3 11b-prostaglandin reductase activity in
KG1a cells was assessed in the presence of a dose titration of 4-MDDT or 5 mM MPA using 3H-PGD2 and thin layer chromatography. Data shown is
mean of N¼ 4 experiments±s.e.m. *Po0.01.
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3H-PGD2 turnover analysis by thin layer chromatography.
AKR1C3-mediated PGD2 turnover in intact cells was determined
by thin layer chromatography as described previously (Desmond
et al, 2003; Davies et al, 2009).
Measurement of cell viability. HL60, KG1a and K562 cell
viability was measured using manual counts, or by flow cytometry
on a BD FACSCalibur utilising Cell Quest Pro software
(Becton Dickinson, Plymouth, UK), viable gates and fluorescent
Cytocount beads (DakoCytomation, Ely, UK).
Assessment of cell differentiation. HL-60 cells were treated for
7 days with re-feeding and re-treating every 2 days. Differentiation
was assessed by flow cytometry (Becton Dickinson FACS Calibur
and Becton Dickinson Cell Quest software) using PE-CD11b
(Becton Dickinson).
Jenner–Giemsa staining of slides. Cytospins were prepared from
75–100 ml of culture. Slides were air dried, methanol fixed and
stained as described previously (Khanim et al, 2009a).
RESULTS
The four human AKR1C enzymes share greater than 86% amino-
acid sequence identity and, also share overlapping substrate
promiscuities (Deyashiki et al, 1994; Dufort et al, 1996; Velica
et al, 2009). Thus identifying inhibitors selective for individual
enzymes from this subfamily represents a considerable challenge.
To this end we have developed a readily accessible indirect AKR1C
fluorescence-based assay that can be used for high-throughput
screening (Supplementary Figure 1). The assay utilises the pan-
human AKR1C substrate PQ and NADPH as cofactors and
measures AKR1C activity indirectly by determining levels of
NADPH remaining in the presence or absence of inhibitor
(Supplementary Figure 1).
As part of our drug redeployment strategy in leukaemia and
lymphoma, we have assembled a library (FMC1) of 100 off-patent
commonly used drugs of a known toxicological profile. This library
has been constructed to reflect each of the drug’s peak serum
concentration and differs from other libraries that normally
contain drugs at a common arbitrary concentration. The FMC1
library was screened initially at 10 peak serum concentrations
against recombinant AKR1C1, -1C2, -1C3 and -1C4 using
the AKR1C-diaphorase-based assay (Figure 1). Indomethacin and
MPA were included as control inhibitors. Wells were included
containing enzyme and no inhibitor (þ ve control) and without
enzyme or inhibitor ( ve control). This screen identified the
broad-spectrum polyketide antibiotic tetracycline as a potential
AKR1C3-selective inhibitor (Figure 1A).
Tetracycline is known to be unstable with factors such as light,
temperature, and pH strongly affecting its chemical stability (Bagga
et al, 2005; Patriciu et al, 2005; Feng et al, 2006). Under alkaline
conditions, tautomerisation, demethylation, and the formation of
terranoic acid and isoforms have been described (Guan and Xiong,
2011). Under acidic conditions, epimerisation reactions of
tetracyclines take place (Patriciu et al, 2005; Wang et al, 2010) to
give 4-epimeric, anhydrous, a/b apo, and ter forms (Guan and
Xiong, 2011). As the solution of tetracycline hydrate in DMSO
being tested was observed to change colour within a few days, the
solution was subjected to reverse-phase HPLC analysis that
revealed the rapid conversion of the dissolved tetracycline to an
unknown breakdown product. Freshly prepared tetracycline
solutions demonstrated no AKR1C3-inhibitory activity; the
AKR1C3-selective activity of the stored solution was shown to be
due to the breakdown product, the presence of which was
confirmed by column chromatography. The purified tetracycline
breakdown product was analysed by MS to give a suggested Mr of
413, which differed byB31Da from the actual mass of tetracycline
(444.43Da). This tetracycline breakdown moiety was subjected to
NMR analysis of its structure, which identified a substitution at
carbon 4 replacing the dimethylamino group with a methyl group
(Figure 1B; Supplementary Tables 1–3). Searches of several
databases (www.chemspider.com, http://pubchem.ncbi.nlm.nih.gov)
did not identify any other tetracycline derivatives with a
similar structure. Hence, to our knowledge this is the first
description of this tetracycline derivative that we have termed
4-methyl,(didemethyl)-tetracycline (4-MDDT) to distinguish
from the 4-dimethylamino,6-methyl-tetracycline parent molecule.
Analysis of the purified compound in the AKR1C-diaphorase assay
confirmed that the selective AKR1C3-inhibitory activity resided in
CONT
BEZ
MPA
Pr
op
id
iu
m
 io
di
de
0
CO
NT MP
A
4-M
DD
T
MP
A/4
-M
DD
T
20
40
60
80
100
%
 A
nn
ex
in
 V
-p
os
itiv
e 
ce
lls
– BEZ
+ BEZ*
*
104
103
102
101
100
104
103
102
101
100
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
100 101 102 103 104 100 101 102 103 104 100 101 102 103 104
100 101 102 103 104
MPA/ 4-MDDT4-MDDT
BEZ /MPA (BaP) BEZ/ 4-MDDT
Annexin V
Figure 4. 4-MDDT does not recapitulate the actions of MPA against primary CLL cells. Peripheral blood mononuclear cells from CLL patients
were cultured on non-CD40L-expressing stroma in a ratio of 10 : 1 in 96-well plates. Treatments with either solvent control, 0.5mM BEZ, 5 mM MPA,
BEZ/MPA (BaP), 5.1mM 4-MDDT, MPA/4-MDDT or BEZ/4-MDDT were performed in triplicate for 24 h, before harvesting and staining with Annexin
V (AV) and propidium iodide (PI), and analysis by flow cytometry. Plot shown is for n¼ 4 samplesþ s.e.m.
AKR1C3 inhibitors lack anti-leukaemic activity BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.83 1511
the 4-MDDT derivative (Figure 1C) and not the parent compound
and had an IC50 of 0.51 mM (Figure 1D). 4-MDDT is more stable
compared with the parent compound.
To interrogate the basis of the specificity of 4-MDDT for
AKR1C3, we performed ligand-protein docking calculations using
our published AKR1C3 structure (Figure 2) (Lovering et al, 2004).
Given the uncertain proton configuration and the flexibility of both
ligand and protein, we did not anticipate finding the exact binding
orientation of 4-MDDT in the active site but anticipated some
insights into ligand specificity. Tetracycline is generally found
associated with a magnesium ion, so we performed docking
experiments both in the presence and absence of magnesium to
determine if this affected the analysis. Our calculations indicate
that magnesium-bound tetracycline is too large for the active site of
the AKR1C3 crystal structure, whereas magnesium-bound
4-MDDT fits (Figure 2). This discrimination was less obvious
for non-magnesium-bound ligands. Given the experimental data,
this would seem to support the binding of 4-MDDT with a
bound magnesium. With regard to understanding AKR1C3
selectivity, the docked 4-MDDT contacted residues of AKR1C3
that differ greatly in physicochemical properties from those of the
other AKR1C subfamily members, notably S118 (c.f. F), S129
(c.f. I/L), R226 (c.f P/L) and F306 (c.f. L/V) (Figure 2B). Given the
otherwise highly similar sequences between the AKR1C isoforms
(Figure 2C), we might anticipate these residues in AKR1C3 to
be of significance. However, a detailed description of the
mechanism of 4-MDDT selectivity for AKR1C3 will require
detailed crystallography studies.
We next turned to investigating the action of 4-MDDT against
HL-60, K562 and KG1a AML cell lines. As previously described
(Khanim et al, 2009a), 5mM MPA alone had a moderate but
statistically anti-proliferative effect on all three AML cell lines and
greatly enhanced AML cell killing when combined with BEZ
(Figure 3A). In contrast, 50 mM 4-MDDT did not display these
activities (Figure 3A). We also previously demonstrated that the
action of BEZ and MPA (BaP) against K562 and KG1a cells was
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mediated by direct cell killing but that in the case of HL-60 cell
death was preceded by the onset of cell differentiation
(Khanim et al, 2009b). Here, we again observed that MPA, when
combined with BEZ, strongly promoted HL-60 cell differentiation
as measured by expression of CD11b and phenotypic changes
(Figure 3B and C). However, the effect of 4-MDDT was very much
reduced (Figure 3B and C). Finally, as previously observed,
MPA promoted the differentiation of HL-60 cells in response to
ATRA but again 4-MDDT did not (Figure 3D). The failure of
4-MDDT to exert MPA-like activities were not due to a failure
to enter cells and inhibit AKR1C3 as demonstrated by the
inhibition of intracellular 11b-PGD2-ketoreductase activity in
KG1a cells (Figure 3E).
Our previous studies demonstrated that the anti-leukaemic
actions of MPA, when combined with BEZ, extended to CLL cells
(Hayden et al, 2009). We therefore tested 4-MDDT alone and in
combination with BEZ or MPA against four primary CLL samples.
As previously reported, neither BEZ nor MPA as single agents
markedly increased apoptosis of CLL cells, but the combination
(BaP) markedly increased apoptosis. Similarly 4-MDDT had little
effect against CLL cells but unlike MPA did not induce apoptosis
when combined with BEZ (Figure 4).
These findings suggested that inhibition of AKR1C3 alone is not
adequate to exert an anti-leukaemic effect. To further test
this hypothesis, we screened a large panel of small chemical
compounds from the NCI diversity set for alternative AKR1C3-
selective inhibitors using the AKR1C-diaphorase assay. The IC50
values of compounds demonstrating AKR1C3 selectivity against all
AKR1C isoforms was measured using the NADPH assay.
As shown in Figure 5A, this screen identified 10 compounds that
showed varying degrees of AKR1C3-selective inhibition. Four of
these compounds were selected for analysis of their actions against
HL-60, K562 and KG1a cells when used alone and when in
combination with BEZ (Figure 5B; Supplementary Figure 2). As in
the case of 4-MDDT, none of the NCI compounds matched the
anti-proliferative actions of MPA and none accentuated cell killing
in the presence of BEZ (Figure 5B). An independent screen,
using an alternative assay (Hebert et al, 2013), of the CRT small-
molecule library identified three distinct chemical series (A1, A6,
A9) (Supplementary Figure 3) also displaying AKR1C3 selectivity.
Inhibition of intracellular AKR1C3 activity as measured using a
11b-PGD2-ketoreductase TLC assay for representative inhibitors in
each of these classes identified low nM IC50 values (3–68 nM)
clearly demonstrating the effective penetrance of these agents
into cells (Figure 6A). Despite this, these agents again did not
recapitulate the combinatorial anti-leukaemic activity with BEZ
displayed by the pan-AKR inhibitor MPA (Figure 6B).
At first sight these new observations appear to contradict our
previous observations that overexpression of AKR1C3 demotes
HL-60 differentiation in response to ATRA and that indomethacin
and MPA demonstrably inhibit AKR1C3 in AML cells and exert
anti-leukaemic activity (Desmond et al, 2003; Khanim et al, 2009a).
However, we have reported that AML cells variably co-express
AKR1-C1, -1C2 and -1C3 (Birtwistle et al, 2009). We have also
demonstrated that both jasmonic acid and methyl jasmonate,
which inhibited AKR1C2 and -1C3 predominantly but also had
had some activity against AKR1C1 and -1C4, were sufficient to
promote apoptosis and/or differentiation in leukaemia cell
(Davies et al, 2009). A unifying explanation would be that the
leukaemic properties of AML cells are reinforced by the combined
activity of these enzymes and that pan-inhibitors are required to
circumvent this. In this regard our screens of the NCI diversity set
identified a compound, NCI-pan inhibitor (NCI-PI) that at 10mM
exhibited inhibitory activities against AKR1C1 -1C2 and -1C3.
When used at 25 mM this compound faithfully recapitulated
the anti-leukaemic actions of MPA against HL-60 and K562
(Figure 7A and B).
DISCUSSION
These studies have identified 4-MDDT, a novel tetracycline
breakdown product, as an excellent lead compound for the
development of a specific AKR1C3 inhibitor. 4-MDDT was able to
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inhibit AKR1C3 enzyme activity in both recombinant enzyme
assays and also in intact cells (Figures 1C and 3E). The relationship
to a widely used antibiotic identifies this compound as a candidate
for hit-to-lead development alongside the development of
indomethacin-based analogues (Byrns et al, 2012; Liedtke et al,
2013). In parallel, alternative strategies using two different assays
systems and compound libraries identified a further seven
AKR1C3-selective inhibitors (Figures 5A and 6) with IC50 values
against recombinant AKR1C3 protein ranging from 3 nM to
B25 mM. The structures of the NCI and CRT compounds are
highly diverse, although all of them have at least 1 6-carbon ring
(Supplementary Figures 2 and 3).
Despite these inhibitory activities against recombinant AKR1C3
protein in biochemical assays, our in vitro cell data indicates
that, at least in AML and CLL, a selective AKR1C3 agent has no
or little anti-neoplastic activity, as none of the inhibitors reduced
cell proliferation, increased differentiation or induced apoptosis in
our cell models. This has significant implications for the
development of AKR1C3 inhibitors as anti-neoplastic agents and
highlights the need to have biological assays integrated into drug
development strategies.
In contrast, the pan AKR1C1, -1C2 and -1C3 inhibitor NCI-PI
faithfully recapitulated the actions of MPA. Given that the
chemical structure of NCI-PI is dissimilar to MPA, it appears
likely that the shared anti-leukaemic actions of these compound
are mediated by their shared ability to inhibit AKR1C isoforms
rather than other shared ‘off-target’ effects. This argument is
further reinforced by similar anti-leukaemic actions of other
structurally diverse AKR1C inhibitors including indomethacin and
jasmonates (Desmond et al, 2003).
Although not immediately tractable as an anti-leukaemic agent,
the availability of 4-MDDT as a research tool will enable
investigators interested in other disease settings to ascertain
whether selective AKR1C3 inhibitors have potential utility and
for studies of the biology of AKR1C3 in various cells. For example,
it will be interesting to test whether 4-MDDT or any of the other
identified AKR1C3-selective inhibitors can restore sensitivity to
anticancer drugs, such as doxorubicin and oracin and cisplatin,
where AKR1C3 has been shown to contribute to the development
of drug resistance (Adegoke and Nyokong, 2012; Adegoke et al,
2012a, b).
In summary, we demonstrate that 4-MDDT provides an
excellent lead structure with proven drug-like qualities, pharma-
cokinetics and toxicity profile for the development of AKR1C3
inhibitors. However, our findings suggest that, at least in AML,
selective inhibition of AKR1C3 is insufficient to elicit an anticancer
effect.
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